Details About Generic Salt ::  Reteplas

Main Medicine Class:: Tissue plasminogen activator.   

(REH-tuh-place)
Retavase
Class: Tissue plasminogen activator.

 

Drugs Class ::

 Action Aids in dissolution of blood clots.

Indications for Drugs ::

 Indications Management of acute MI, to reduce incidence of congestive heart failure and mortality associated with an acute MI.

Drug Dose ::

 Route/Dosage

ADULTS: IV 10 + 10 U double-bolus injection, each bolus given over 2 mins. The second bolus given 30 mins after initiation of the first.

Contraindication ::

 Contraindications Active internal bleeding; history of cerebrovascular accident; recent intracranial or intraspinal surgery or trauma; intracranial neoplasm, arteriovenous malformation or aneurysm; bleeding diathesis or severe uncontrolled hypertension because thrombolytic therapy increases the risk of bleeding.

Drug Precautions ::

 Precautions

Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy not established. Bleeding: Most frequent and serious side effect. Arrhythmias: Antiarrhythmic therapy should be available because coronary reperfusion may result in arrhythmias.

PATIENT CARE CONSIDERATIONS


Drug Side Effects ::

 Adverse Reactions

HEMA: Bleeding, both superficial (eg, venous cutdowns, arterial punctures, sites of surgical intervention), and internal (eg, GI tract, GU tract, pericardial, retroperitoneal sites).

Drug Mode of Action ::  

 Action Aids in dissolution of blood clots.

Drug Interactions ::

 Interactions

Abciximab, aspirin, dipyridamole, heparin, vitamin K antagonists: May increase the risk of bleeding. INCOMPATIBILITIES: Heparin: Do not add other medications to the same IV.

Drug Assesment ::

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies. Note cerebrovascular disease, hypertension or recent internal bleeding.
  • Obtain drug history, noting use of aspirin, dipyridamole or heparin because these drugs may increase the risk of bleeding.
  • Ensure that coagulation studies have been performed before administration. These tests provide baseline values against which to monitor patient’s response to therapy.
  • Take pulse and BP before administration and monitor frequently during infusion.
  • Observe for internal or external bleeding before and during infusion.
  • Carefully monitor potential bleeding sites (eg, catheter insertion sites, arterial puncture sites) because fibrin will be lysed during therapy, resulting in new or increased bleeding.
  • Avoid IM injections and nonessential handling of patient during treatment.
  • Minimize number of arterial and venous punctures.
  • If arterial punctures are necessary, use site accessible to manual compression. Use manual pressure for at least 30 min, apply pressure and check site frequently for evidence of bleeding.
  • If serious bleeding occurs, stop infusion and any concomitant heparin and notify physician.
  • Observe for indications of hypersensitivity (eg, urticaria, fever). Nausea, vomiting, hypotension and fever are frequent sequelae of MI and may or may not be attributable to therapy.
  • If anaphylactic reaction occurs, stop infusion, notify physician and initiate appropriate therapy.
OVERDOSAGE: SIGNS & SYMPTOMS
  Bleeding.

Drug Storage/Management ::

 Administration/Storage

  • Available only as powder for reconstitution for IV administration.
  • Administer by IV infusion only.
  • Reconstitute immediately before use; only with accompanying Sterile Water for Injection (without preservatives) following reconstitution instructions. Do not shake.
  • Allow to stand after reconstitution until all large bubbles are dissipated.
  • Solution may be stored up to 4 hrs at room temperature (36°–86°F).
  • Do not administer if solution is discolored or if particles are present.
  • Store at room temperature. Protect from light.

Drug Notes ::

 Patient/Family Education

  • Explain drug action and need for frequent monitoring, including blood tests and vital signs.
  • Instruct patient to report any new bleeding sites or increased bleeding, dizziness, headache, numbness or tingling.
  • Tell patient to report urticaria or fever.
  • Instruct patient to avoid getting out of bed without assistance during treatment.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.

DOWNLOAD OUR ANDROID APP

One of the 1st in India.High Quality Generic Medicine Portal Android Application for Online Oreder & Information.

For More Join Our Membership and Get Additional 25% off on Meds, also get MLM Benefits to get a permanent earning source.

Join Membership How to Search Medicine
Android App

We would like to keep you updated with special notifications.